China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, Beijing Wanhui Double Crane Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its alfacalcidol soft capsules, according to a Tuesday disclosure on the Shanghai bourse.
The drug is used for the treatment of calcium metabolism disorders.
The cumulative investment for the research and development of the drug amounted to 4.9 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments